SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
复制标题
DOI：
10.1126/science.abm0620
复制
发表时间：
2022-01-21
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
我们报告了严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）疫苗对退伍军人健康管理局780,225名退伍军人（占美国人口的2.7%）感染（VE-I）和死亡（VE-D）的疫苗类型的有效性。从2021年2月至10月，所有疫苗类型的VE-I均下降，杨森疫苗的VE-I下降幅度最大，为13.1%。尽管突破性感染增加了死亡风险，但在德尔塔病毒变体激增期间感染的人接种疫苗仍可防止死亡。从2021年7月到10月，年龄<65岁的VE-D在杨森为73.0%，Moderna为81.5%，辉瑞- biontech为84.3%；年龄≥65岁的VE-D，杨森为52.2%，Moderna为75.5%，辉瑞- biontech为70.1%。研究结果支持继续努力增加疫苗接种、加强运动和多重额外的感染保护。美国退伍军人事务部（VA）为军人提供终身医疗保健，VA数据为美国公共卫生监测提供了独特的资源。Cohn等人检查了来自78万多人的数据，以追踪2021年2月至9月期间美国出现严重急性呼吸综合征冠状病毒2 (SARS-CoV-2) δ变体时疫苗接种的效果。尽管信使RNA （mRNA）和病毒载体疫苗已经有效地预防了临床上重要的疾病，但SARS-CoV-2德尔塔病毒的传播却激增。疫苗突破感染主要发生在接种病毒载体疫苗的人群中，但也发生在接种mRNA疫苗的人群中。到2021年9月，研究期间病毒载体疫苗提供的预防感染的保护率降至约13%，预防死亡的保护率降至约50%。未接种疫苗的人仍然处于感染、严重疾病和死亡的最高风险。随着Delta变体在美国出现，到2021年8月，针对SARS-CoV-2感染的疫苗保护作用一直在下降。
We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type in 780,225 veterans in the Veterans Health Administration, covering 2.7% of the US population. From February to October 2021, VE-I declined for all vaccine types, and the decline was greatest for the Janssen vaccine, resulting in a VE-I of 13.1%. Although breakthrough infection increased risk of death, vaccination remained protective against death in persons who became infected during the Delta variant surge. From July to October 2021, VE-D for age <65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age ≥65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech. Findings support continued efforts to increase vaccination, booster campaigns, and multiple additional layers of protection against infection. The US Department of Veterans Affairs (VA) provides life-long healthcare to military personnel, and VA data offer a unique resource for public health surveillance in the United States. Cohn et al. examined data from over 780,000 individuals to track the effects of vaccination rollout as the Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the United States between February and September of 2021. Although messenger RNA (mRNA) and viral vector vaccines have effectively prevented clinically significant disease, SARS-CoV-2 Delta transmission has surged. Vaccine breakthrough infections have predominated in those given the viral vector vaccine but also occur among those given mRNA vaccines. By September 2021, the protection offered by the viral vector vaccine during the study declined to about 13% against infection and to about 50% against death. Unvaccinated individuals remained at the highest risk of infection, severe disease, and death. —CA Vaccine protection against SARS-CoV-2 infection declined through August 2021 as the Delta variant emerged in the United States.
登录
查看更多内容
DOI：
10.1056/nejmoa2113017
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
El Sahly HM;Baden LR;Essink B;Doblecki-Lewis S;Martin JM;Anderson EJ;Campbell TB;Clark J;Jackson LA;Fichtenbaum CJ;Zervos M;Rankin B;Eder F;Feldman G;Kennelly C;Han-Conrad L;Levin M;Neuzil KM;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Polakowski L;Mascola JR;Ledgerwood JE;Graham BS;August A;Clouting H;Deng W;Han S;Leav B;Manzo D;Pajon R;Schödel F;Tomassini JE;Zhou H;Miller J;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.15585/mmwr.mm7023e2externalicon
发表时间：
2021-06-11
影响因子：
33.9
作者：
Christie, Athalia;Henley, Jane;Beach, Michael J.
通讯作者：
Beach, Michael J.
DOI：
10.15585/mmwr.mm7037e3
发表时间：
2021-09-17
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Bajema KL;Dahl RM;Prill MM;Meites E;Rodriguez-Barradas MC;Marconi VC;Beenhouwer DO;Brown ST;Holodniy M;Lucero-Obusan C;Rivera-Dominguez G;Morones RG;Whitmire A;Goldin EB;Evener SL;Tremarelli M;Tong S;Hall AJ;Schrag SJ;McMorrow M;Kobayashi M;Verani JR;Surie D;SUPERNOVA COVID-19;Surveillance Group;Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) COVID-19 Surveillance Group
通讯作者：
Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) COVID-19 Surveillance Group
影响因子：
82.9
作者：
Chemaitelly, Hiam;Yassine, Hadi M.;Abu-Raddad, Laith J.
通讯作者：
Abu-Raddad, Laith J.
影响因子：
1.7
作者：
Brusselaers, Nele;Lagergren, Jesper
通讯作者：
Lagergren, Jesper